{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:46:44Z","timestamp":1782733604541,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["MYRG-GRG2024-00147-ICMS-UMDF"],"award-info":[{"award-number":["MYRG-GRG2024-00147-ICMS-UMDF"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["MYRG-CRG2024-00024-ICMS-IAS"],"award-info":[{"award-number":["MYRG-CRG2024-00024-ICMS-IAS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.reth.2026.101102","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:41:56Z","timestamp":1773823316000},"page":"101102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China"],"prefix":"10.1016","volume":"32","author":[{"given":"Junnan","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-5099","authenticated-orcid":false,"given":"Carolina Oi Lam","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2026.101102_bib1","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the value of gene therapy and enhancing patient access to transformative treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.reth.2026.101102_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fbioe.2018.00130","article-title":"Recent progress in European advanced therapy medicinal products and beyond","volume":"6","author":"Yu","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.reth.2026.101102_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymthe.2023.12.003","article-title":"Gene and cell therapy in 2023: rich pipeline, slimming resources?","volume":"32","author":"High","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.reth.2026.101102_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjinnov-2020-000425","article-title":"Patient access to gene therapy medicinal products: a comprehensive review","volume":"7","author":"Carvalho","year":"2021","journal-title":"BMJ Innov"},{"key":"10.1016\/j.reth.2026.101102_bib5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.reth.2026.101102_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-031-34567-8_9","article-title":"Regulatory aspects of cell and gene therapy products: the Japanese perspective","volume":"1430","author":"Maruyama","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.reth.2026.101102_bib8","series-title":"Managing the challenges of paying for gene therapy: strategies for market action and policy reform","author":"Phares","year":"2024"},{"key":"10.1016\/j.reth.2026.101102_bib9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jcyt.2024.04.070","article-title":"The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards","volume":"26","author":"Shi","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101102_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3721","article-title":"Gene therapy clinical trials worldwide to 2023-an update","volume":"26","author":"Ginn","year":"2024","journal-title":"J Gene Med"},{"key":"10.1016\/j.reth.2026.101102_bib11","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ymthe.2025.05.014","article-title":"China's first approved gene therapy for hemophilia B: a new era for global AAV-based treatments","volume":"33","author":"Wei","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.reth.2026.101102_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/jmahp12020008","article-title":"EU HTA regulation and joint clinical assessment\u2014threat or opportunity?","volume":"12","author":"Schuster","year":"2024","journal-title":"J Market Access Health Policy"},{"key":"10.1016\/j.reth.2026.101102_bib15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/polym16091280","article-title":"Progress in wound-healing products based on natural compounds, stem cells, and microRNA-based biopolymers in the European, USA, and Asian markets: opportunities, barriers, and regulatory issues","volume":"16","author":"Srivastava","year":"2024","journal-title":"Polymer"},{"issue":"1","key":"10.1016\/j.reth.2026.101102_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101403","article-title":"Ensuring patient access to gene therapies for rare diseases: navigating reimbursement and coverage challenges","volume":"33","author":"Berry","year":"2025","journal-title":"Mol Ther, Methods Clin Dev"},{"key":"10.1016\/j.reth.2026.101102_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00103-009-0985-3","article-title":"Regulation (EC) No. 1394\/2007 on advanced therapy medicinal products: incorporation into national law","volume":"53","author":"Dwenger","year":"2010","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"key":"10.1016\/j.reth.2026.101102_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2020.11.008","article-title":"Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States","volume":"23","author":"Iglesias-Lopez","year":"2021","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.reth.2026.101102_bib19","first-page":"683","article-title":"Regulatory considerations for gene therapy products in the US, EU, and Japan","volume":"90","author":"Halioua-Haubold","year":"2017","journal-title":"Yale J Biol Med"},{"issue":"7","key":"10.1016\/j.reth.2026.101102_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reth.2026.101102_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"key":"10.1016\/j.reth.2026.101102_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13012-021-01168-2","article-title":"Market viability: a neglected concept in implementation science","volume":"16","author":"Proctor","year":"2021","journal-title":"Implement Sci"},{"key":"10.1016\/j.reth.2026.101102_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13012-020-00993-1","article-title":"A pragmatic method for costing implementation strategies using time-driven activity-based costing","volume":"15","author":"Cidav","year":"2020","journal-title":"Implement Sci"},{"issue":"1","key":"10.1016\/j.reth.2026.101102_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13012-021-01176-2","article-title":"Meta-review of implementation determinants for policies promoting healthy diet and physically active lifestyle: application of the Consolidated Framework for Implementation Research","volume":"17","author":"Lobczowska","year":"2022","journal-title":"Implement Sci"},{"key":"10.1016\/j.reth.2026.101102_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/frhs.2023.1291183","article-title":"Combining legal epidemiology and implementation science to improve global access to medicines: challenges and opportunities","volume":"3","author":"Lane","year":"2024","journal-title":"Frontiers in Health Services"},{"issue":"2","key":"10.1016\/j.reth.2026.101102_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jval.2024.10.3848","article-title":"Financial impacts of paying for gene therapy for sickle cell disease under alternative pricing and financing mechanisms","volume":"28","author":"Basu","year":"2025","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.reth.2026.101102_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s43441-025-00769-z","article-title":"Beyond reimbursement status: availability of advanced therapy medicinal products across the European Union","volume":"59","author":"\u010cechov\u00e1","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.reth.2026.101102_bib28","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.clinthera.2024.11.019","article-title":"A systematic review of challenges and opportunities in the implementation of managed entry agreements for advanced therapy medicinal products","volume":"47","author":"Greco","year":"2025","journal-title":"Clin Ther"},{"key":"10.1016\/j.reth.2026.101102_bib29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jcyt.2025.01.008","article-title":"Sickle cell disease gene therapy drug expenses and reimbursement: a litmus test for commercial pricing strategy and patient access for curative therapies","volume":"27","author":"Grilley","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101102_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jval.2024.08.009","article-title":"Challenges in value assessment for one-time gene therapies for inherited retinal diseases: are we turning a blind eye?","volume":"28","author":"Hitch","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.reth.2026.101102_bib31","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1017\/S0266462324000096","article-title":"A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: whether a specific approach is justified to tackle the challenges?","volume":"40","author":"Qiu","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.reth.2026.101102_bib32","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jval.2024.07.007","article-title":"Linking reimbursement to patient benefits for advanced therapy medicinal products and other high-cost innovations: policy recommendations for outcomes-based agreements in Europe","volume":"27","author":"Av\u015far","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.reth.2026.101102_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1163\/15718093-bja10121","article-title":"What are the changes in 2023 for access to advanced therapy medicinal products (ATMPs) in France?","volume":"31","author":"Bartos","year":"2024","journal-title":"Eur J Health Law"},{"key":"10.1016\/j.reth.2026.101102_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.13485","article-title":"ESOT roadmap for advanced therapy medicinal products in transplantation: navigating regulatory challenges to enhance access and care","volume":"37","author":"Berishvili","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.reth.2026.101102_bib35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40259-024-00683-0","article-title":"Advanced therapy medicinal products: availability, access and expenditure in Italy","volume":"38","author":"Rivetti di Val Cervo","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.reth.2026.101102_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12913-023-09494-5","article-title":"How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?","volume":"23","author":"Drummond","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.reth.2026.101102_bib37","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1377\/hlthaff.2023.00527","article-title":"Confronting high costs and clinical uncertainty: innovative payment models for gene therapies","volume":"42","author":"Horrow","year":"2023","journal-title":"Health Aff"},{"key":"10.1016\/j.reth.2026.101102_bib38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.stem.2023.07.004","article-title":"Regulation of advanced therapies in Europe: are we on the right track?","volume":"30","author":"Izeta","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.reth.2026.101102_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jval.2022.07.004","article-title":"Challenges for economic evaluations of advanced therapy medicinal products: a systematic review","volume":"26","author":"Olry de Labry-Lima","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.reth.2026.101102_bib40","article-title":"Cell and gene therapy regulatory, pricing, and reimbursement framework: with a focus on South Korea and the EU","volume":"11","author":"Eu Lee","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.reth.2026.101102_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14737167.2023.2159813","article-title":"Medicaid best price reforms to enable innovative payment models for cell and gene therapies","volume":"23","author":"Quinn","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.reth.2026.101102_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1199500","article-title":"Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries","volume":"14","author":"Rejon-Parrilla","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.reth.2026.101102_bib43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41434-023-00402-4","article-title":"Approval and therapeutic value of gene therapies in the US and Europe","volume":"30","author":"Vokinger","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.reth.2026.101102_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.therap.2021.11.005","article-title":"Advanced therapy medicinal products: regulatory framework, hospital and pharmaceutical circuits in Europe and France","volume":"77","author":"Mebarki","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.reth.2026.101102_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40290-022-00443-x","article-title":"Pricing and market access challenges in the era of one-time administration cell and gene therapies","volume":"36","author":"Sabatini","year":"2022","journal-title":"Pharm Med (Lond)"},{"key":"10.1016\/j.reth.2026.101102_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.771966","article-title":"Critical reflections on reimbursement and access of advanced therapies","volume":"13","author":"Simoens","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.reth.2026.101102_bib47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jval.2021.09.012","article-title":"Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, the Netherlands, and England","volume":"25","author":"Ten Ham","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.reth.2026.101102_bib48","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1017\/jme.2022.66","article-title":"High-priced sickle cell gene therapies threaten to exacerbate US health disparities and establish new pricing precedents for molecular medicine","volume":"50","author":"Tessema","year":"2022","journal-title":"J Law Med Ethics"},{"key":"10.1016\/j.reth.2026.101102_bib49","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/bcp.14286","article-title":"Managing access to advanced therapy medicinal products: challenges for NHS Wales","volume":"87","author":"Champion","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reth.2026.101102_bib50","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jval.2021.05.008","article-title":"Hemophilia gene therapy value assessment: methodological challenges and recommendations","volume":"24","author":"Garrison","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.reth.2026.101102_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.755052","article-title":"Health technology assessment of advanced therapy medicinal products: Comparison among 3 European countries","volume":"12","author":"Gozzo","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.reth.2026.101102_bib52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41431-021-00877-y","article-title":"Moving somatic gene editing to the clinic: routes to market access and reimbursement in Europe","volume":"29","author":"Rigter","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.reth.2026.101102_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40545-021-00311-0","article-title":"Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?","volume":"14","author":"Ronco","year":"2021","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.reth.2026.101102_bib54","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.healthpol.2021.10.003","article-title":"Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe","volume":"125","author":"Tunis","year":"2021","journal-title":"Health Policy"},{"key":"10.1016\/j.reth.2026.101102_bib55","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40273-020-00956-w","article-title":"Recalibrating health technology assessment methods for cell and gene therapies","volume":"38","author":"Angelis","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.reth.2026.101102_bib56","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10198-020-01212-w","article-title":"HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies","volume":"21","author":"Coyle","year":"2020","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.reth.2026.101102_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10198-019-01147-x","article-title":"Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment","volume":"21","author":"Gon\u00e7alves","year":"2020","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.reth.2026.101102_bib58","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14740\/jocmr3964","article-title":"Advanced therapy medicinal products challenges and perspectives in regenerative medicine","volume":"12","author":"Goula","year":"2020","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.reth.2026.101102_bib59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1163\/15718093-BJA10016","article-title":"Exploring solutions to foster ATMP development and access to patients in Europe","volume":"27","author":"Salvatore","year":"2020","journal-title":"Eur J Health Law"},{"key":"10.1016\/j.reth.2026.101102_bib60","first-page":"1162","article-title":"HTA'd in the USA: a comparison of ICER in the United States with NICE in England and Wales","volume":"26","author":"Thokala","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.reth.2026.101102_bib61","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s10198-025-01790-7","article-title":"Challenges and reforms in Spain\u2019s health technology assessment system: analysis of criteria influencing medicines\u2019 reimbursement decisions between 2019 and 2022 in Spain","volume":"26","author":"Pinilla-Dominguez","year":"2025","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.reth.2026.101102_bib63","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1017\/S026646232500008X","article-title":"Value and implementation of patient and public involvement and engagement in health technology assessment for Japan: implications from systematic searches","volume":"41","author":"Kaneyasu","year":"2025","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.reth.2026.101102_bib64","series-title":"Joint statement on proposals for the 2024 drug pricing reform","year":"2024"},{"key":"10.1016\/j.reth.2026.101102_bib67","first-page":"8543","article-title":"A new outcomes-based payment plan from a Chinese company to improve patient affordability of CAR-T product","volume":"13","author":"Zheng","year":"2024","journal-title":"Int J Health Pol Manag"},{"key":"10.1016\/j.reth.2026.101102_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12992-019-0524-4","article-title":"Japan: achieving UHC by regulating payment","volume":"15","author":"Ikegami","year":"2019","journal-title":"Glob Health"},{"key":"10.1016\/j.reth.2026.101102_bib70","article-title":"Promoting access to innovative anticancer medicines: a review of drug price and national reimbursement negotiation in China","volume":"60","author":"Mingge","year":"2023","journal-title":"Inquiry"},{"issue":"1","key":"10.1016\/j.reth.2026.101102_bib72","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12916-024-03637-z","article-title":"Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study","volume":"22","author":"Cai","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.reth.2026.101102_bib73","series-title":"Adopted value assessment methods for high-impact single or short-term therapies","year":"2022"},{"key":"10.1016\/j.reth.2026.101102_bib74","series-title":"Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations","year":"2019"},{"issue":"6","key":"10.1016\/j.reth.2026.101102_bib76","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jcyt.2025.02.010","volume":"27","author":"Noda","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101102_bib77","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.jcyt.2018.07.008","article-title":"Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility","volume":"20","author":"Digiusto","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101102_bib78","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jcyt.2019.10.010","article-title":"Cell and gene therapy manufacturing capabilities in Australia and New Zealand","volume":"21","author":"O'Sullivan","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101102_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101485","article-title":"The clinical quality management system of advanced therapy medicinal products in the hospital setting: a scoping review","volume":"33","author":"Shi","year":"2025","journal-title":"Mol Ther, Methods Clin Dev"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235232042600043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235232042600043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:20:08Z","timestamp":1782732008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235232042600043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"alternative-id":["S235232042600043X"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2026.101102","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2026.101102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}],"article-number":"101102"}}